Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414999 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
A Phase 1 study of Diabetic Retinopathy and Macular Degeneration, sponsored by TargeGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT00414999: Completed Phase 1 study of Diabetic Retinopathy and Macular Degeneration, sponsored by TargeGen.
NCT00414999 is a Phase 1 study of Diabetic Retinopathy and Macular Degeneration that has completed, run by TargeGen. The registered enrollment target is 44 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414999, a Phase 1 study of Diabetic Retinopathy and Macular Degeneration, has completed, sponsored by TargeGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible, severe loss of vision in people 55 years of age and older in the developed world. TG100801 is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies, and may have great utility in the treatment of diseases such as AMD. The purpose of this study is to assess the safety, ocular tolerability, and blood pharmacokinetics of TG100801 at escalating doses in healthy volunteers.
Conditions Studied
Interventions
- DRUG TG100801
Study Locations (1)
Kansas
- Quintiles Phase One Services, Inc. - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
What the finished NCT00414999 record still lists
NCT00414999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which TG100801 is the first listed.
NCT00414999 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT00414999 about?
NCT00414999 is a clinical study titled "A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers". The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible, severe loss of vision in people 55 years of age and older in the developed w...
What is the current status of trial NCT00414999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2006-11. Estimated completion is 2007-02.
What conditions does trial NCT00414999 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Macular Degeneration.
What interventions are being tested in trial NCT00414999?
The interventions under investigation include: TG100801 (DRUG).
Who is sponsoring clinical trial NCT00414999?
This trial is sponsored by TargeGen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00414999 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00414999's enrollment target sits among peer trials
44 44th of 57 higher than 14 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
COMPLETED · Phase 1
-
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
COMPLETED · Phase 1
-
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
COMPLETED · Phase 1
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia